Last updated: February 22, 2026
What is the Drug Associated with NDC 00006-5370?
NDC 00006-5370 corresponds to Humira (adalimumab), a monoclonal antibody used mainly to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and more. Approved by the FDA in 2002, Humira remains one of the leading biologic drugs worldwide.
Market Overview
Humira generated approximately $21.3 billion in U.S. sales in 2022, according to IQVIA. Its global sales surpassed $22 billion in the same year. The drug maintains dominant market share within biologics for autoimmune diseases, with approximately 60-70% share in multiple indications.
Competitive Landscape
Humira faces competition from biosimilars, particularly in Europe and other regions where patent exclusivity has expired. In the U.S., the biologics patent cliff is imminent, with Bristol-Myers Squibb's Orencia and Amgen's Amjevita (biosimilar) beginning competitive launches.
In 2016, AbbVie began transitioning prescriptions to biosimilars, but the original Humira still accounts for a significant revenue portion. Biosimilar penetration in the U.S. remains limited due to legal and regulatory barriers, yet projections indicate that biosimilars could capture 40-50% of the market within five years of entry.
Patent and Regulatory Status
AbbVie's patent for Humira in the U.S. is set to expire in January 2023, with biosimilar approval and launch increasing. In Europe, multiple biosimilars are already available, reducing prices by up to 60%. Similar market dynamics are expected in the U.S. following patent expiration.
Market Drivers
- Growing prevalence of autoimmune diseases: The incidence of rheumatoid arthritis and Crohn's disease continues to rise, especially among aging populations.
- Expanding indications: Humira is approved for additional conditions, increasing its addressable market.
- Brand loyalty and reimbursement policies: Insurers often favor established biologics, maintaining high utilization rates.
Market Risks
- Patent expiry and biosimilar entry: Erode revenue potential and pressure prices downward.
- Pricing policies: U.S. initiatives to cap drug prices and promote biosimilar substitution could reduce average selling prices (ASPs).
- Manufacturing and supply chain: Requires significant investment; any disruption could adversely impact sales.
Price Projections
Pre-Biosimilar Scenario (2023-2025)
- Current ASP: Approximately $6,000–$6,500 per month per patient.
- Market share: 70-80% of auto-immune treatment prescriptions.
- Projected revenues: $18-21 billion in the U.S. alone.
Post-Biosimilar Entry (2025-2030)
-
Biosimilar penetration: Estimated to reach 50-70% in the U.S.
-
Biosimilar pricing: As much as 60% lower than original biologic.
-
Adjusted ASPs: Expected to decline to $3,000–$3,500 per month.
-
Revenue impact: Domestic sales could decrease by 40-50%, with global sales affected proportionally.
-
Market share shift: Biosimilars are projected to capture the majority of new prescriptions, with Humira’s market share in the U.S. declining to less than 30%.
Long-term Outlook (2030+)
- Market stabilization: Humira’s revenue in North America may stabilize at $5-8 billion annually, mainly from legacy patients.
- Price declines: Average ASPs could fall further (by approximately 70%) relative to peak pre-biosimilar levels.
- Global sales: Will vary based on regional biosimilar adoption policies, with emerging markets exhibiting slower decline.
Investment and Strategic Implications
AbbVie is developing biosimilar competitors (e.g., Cyltezo), aiming to defend market share. The company has also moved towards innovative therapies, including JAK inhibitors and other biologics, to diversify beyond Humira.
Despite impending biosimilar competition, Humira retains substantial revenue due to pre-existing patient access and physician familiarity. Transition strategies, such as switching patients from Humira to biosimilars, may accelerate revenue decline.
Key Takeaways
- Human biologic sales peaked at over $21 billion in 2022.
- Patent expiration in January 2023 will trigger biosimilar competition.
- Prices are expected to decline by 50-70%, with significant market share shifts.
- Long-term revenues could decline by up to half in the U.S. market.
- Diversification into new therapies aims to offset revenue loss.
FAQs
1. When will biosimilar competition significantly impact Humira's sales?
Biosimilars are expected to account for the majority of prescriptions in the U.S. by 2025-2027, leading to considerable price and market share erosion.
2. How much could prices for Humira decrease post-biosimilar entry?
Average ASPs are projected to decline by approximately 50-70%, with U.S. prices dropping from about $6,000–$6,500 to $3,000–$3,500 per month.
3. Will all patients switch to biosimilars once available?
Not necessarily. Physician and patient hesitancy, insurance policies, and specific indications will influence switching rates.
4. How is AbbVie preparing for biosimilar competition?
The company is developing new biologics, alternative therapies, and has launched biosimilar versions (e.g., Cyltezo) to retain market presence.
5. What factors could modify these projections?
Legislative changes, patent litigation outcomes, biosimilar adoption rates, and pricing reforms could alter revenue forecasts.
References
[1] IQVIA Institute. (2023). The Growing Value of Biosimilars in the U.S. Retrieved from https://www.iqvia.com/insights/the-growing-value-of-biosimilars-in-the-us
[2] FDA. (2022). Biologic Product Approvals. U.S. Food and Drug Administration.
[3] AbbVie. (2022). Humira Product Label.
[4] EvaluatePharma. (2022). Global Biosimilars Market Report.
[5] American Hospital Association. (2022). Impact of Patent Expirations on Biologic Drugs.
